HYHideaki Yahata

Hideaki Yahata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hideaki Yahata has a total of 232 co-authors. Here are the top co-authors by number of shared publications:

  • Kiyoko Kato

    Department of Obstetrics and Gynecology Kyushu University Hospital Fukuoka Fukuoka Japan

    16 shared publications
  • Masafumi Yasunaga

    Department of Obstetrics and Gynecology Graduate School of Medical Sciences, Kyushu University Fukuoka Japan

    14 shared publications
  • Hiroshi Yagi

    Department of Obstetrics and Gynecology, Graduate School of Medical Science Kyushu University Fukuoka Japan

    13 shared publications
  • Kiyoko Kato

    Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    13 shared publications
  • Ichiro Onoyama

    Department of Obstetrics and Gynecology Kyushu University Hospital Fukuoka Fukuoka Japan

    12 shared publications
  • Kaoru Okugawa

    Department of Obstetrics and Gynecology Kyushu University Hospital Fukuoka Fukuoka Japan

    12 shared publications

Latest Publications

  • Open Access

    Distinct Rb expression pattern in HPV ‐associated neuroendocrine carcinomas of the uterine cervix

    by Nobuko Yasutake, Misato Komamizu, Takeshi Iwasaki, Ryosuke Kuga, Tomomi Manako, Mikiko Hashisako, Rina Jiromaru, Tomoko Sho, Norihito Yuge, Kenzo Sonoda, et al.

    Aims: This study aimed to characterize high‐risk human papillomavirus (HR‐HPV) infection and the expression patterns of p16, Rb, p53 and cyclin D1 in uterine cervical neuroendocrine carcinomas (UCNECs). We also aimed to clarify the similarities and differences between UCNECs and pulmonary neuroendocrine carcinomas (NECs). Methods and results: We examined the expression patterns of p16, Rb, p53, and cyclin D1 by immunohistochemistry (IHC) and HR‐HPV infection by mRNA in situ hybridization (ISH) in 29 UCNEC cases, along with histological review. Ten pulmonary small cell neuroendocrine carcinomas (SCNECs) were included for comparison. Histologically, most UCNECs were SCNECs combined with adenocarcinoma or squamous cell carcinoma. HR‐HPV ISH was performed in 28 UCNEC cases; 27 (96%) were HPV‐positive and 1 (4%) was HPV‐negative. All HPV‐positive cases ( n = 27) showed p16 overexpression, partial Rb loss, a wildtype p53 pattern, and negative cyclin D1 expression. The single HPV‐negative case showed focal p16 positivity, retained Rb expression, a wildtype p53 pattern and positive cyclin D1 expression. In contrast, all 10 pulmonary SCNEC cases were negative for HR‐HPV and positive for p16, showing complete loss ( n = 9) or retained ( n = 1) Rb expression, and often aberrant p53 expression ( n = 8; 5 diffuse and 3 null). Conclusions: Most UCNECs are associated with HPV infection and characterized by p16 overexpression as well as partial loss of Rb. The Rb expression pattern differs between HPV‐positive UCNECs and HPV‐negative pulmonary NECs, suggesting the potential diagnostic utility of Rb as well as p16.

  • Open Access

    Clinicopathological Differences in HER2 Immunohistochemical Expression Between Low-Grade Endometrial Cancer with p53-Abnormal Expression and High-Grade Endometrial Cancer

    by Kazuhisa Hachisuga, Miya Nakashima, Yoshihiro Katayama, Yusuke Inomata, Hiroshi Tomonobe, Shoji Maenohara, Keisuke Kodama, Hiroshi Yagi, Ichiro Onoyama, Kazuo Asanoma, et al.

    Background/Objectives: Under the current molecular classification of endometrial cancer, the p53-abnormal group is defined as having the worst prognosis, but the clinicopathological position of low-grade endometrial cancer with p53-abnormal expression relative to high-grade endometrial cancer remains unclear. We previously showed that low-grade endometrial cancer with p53-abnormal expression more closely resembles low-grade endometrial cancer with p53 wild-type expression than high-grade endometrial cancer and that the ERBB2 gene, encoding Human Epidermal Growth Factor Receptor 2 (HER2) protein, is more highly expressed in high-grade endometrial cancer. This study compared HER2 immunohistochemical expression (IHC) among low-grade endometrial cancer with wild-type p53 expression (EClop53wt), low-grade endometrial cancer with p53-abnormal expression (EClop53ab), and high-grade endometrial cancer (EChi), in order to characterize EClop53ab. Methods: We retrospectively analyzed 70 endometrial cancer cases treated at Kyushu University Hospital in 1992–2022. Tumors were classified as EClop53wt, EClop53ab, and EChi based on histopathology and p53 immunohistochemistry, with EChi corresponding to conventional uterine serous carcinoma. HER2 expression was evaluated immunohistochemically using a standardized scoring system (0, 1+, 2+, 3+), and its distribution was compared across the three groups, together with clinicopathological parameters and patient outcomes. Results: EChi showed the highest frequency and intensity of HER2 expression, with a substantially larger proportion of HER2 IHC 3+ cases than EClop53wt and EClop53ab (p < 0.0001 and p = 0.0146, respectively). Meanwhile, there was no significant association between EClop53wt and EClop53ab (p = 0.3794). In addition, HER2 IHC 3+ had significant associations with older age (≥60 years) and substantial lymphovascular space invasion (p = 0.0003 and 0.0174, respectively). Conclusions: EClop53ab exhibits HER2 profiles and clinical behavior more similar to EClop53wt, supporting the more nuanced application of molecular classification and HER2-targeted therapy in endometrial cancer.

  • Open Access

    Claudin‐18 expression in gastric type adenocarcinoma and HPV ‐associated adenocarcinoma of the uterine cervix

    by Nobuko Yasutake, Yuki Yokawa, Takehiro Tanaka, Riri Mishima, Misato Komamizu, Ryosuke Kuga, Rina Jiromaru, Shinichiro Kawatoko, Kenzo Sonoda, Hideaki Yahata, et al.

    Aims: Claudin‐18 (CLDN18) is both a marker for the gastric phenotype and a therapeutic target. However, little is known about its immunoexpression in endocervical adenocarcinomas (ECAs), particularly as detected using the clone 43‐14A antibody, or about the gene expression of its isoforms in ECAs. Methods and results: We examined CLDN18, HIK1083, p16 and Rb expression by immunohistochemistry and high‐risk human papillomavirus (HR‐HPV) mRNA by in situ hybridization (ISH) in 121 ECAs, including 35 HPV‐independent adenocarcinomas (gastric type [GAS], n = 24; non‐GAS, n = 11) and 86 HPV‐associated ECAs. We also analysed mRNA expression of the CLDN18.1 (lung type) and CLDN18.2 (gastric type) isoforms by quantitative polymerase chain reaction (qPCR) in selected cases. CLDN18 positivity was detected in 8/24 (33%) GASs, 0/11 (0%) non‐GASs and 2/86 (2%) HPV‐associated ECAs, with positivity defined as staining in ≥75% of tumour cells, as in gastric cancer. When a 5% cut‐off was used, CLDN18 positivity was detected in 22/24 (92%) GASs, 0/11 (0%) non‐GASs and 6/86 (7%) HPV‐associated ECAs; CLDN18 expression was thus significantly associated with GAS histology ( P < 0.0001). Among the 6 cases of HPV‐associated ECAs with CLDN18 expression (ranging from 5% to 80%), the histological patterns included a mix of usual and mucinous features in 4 cases, pure usual type in 1 and villoglandular variant in 1. Otherwise features such as p16 overexpression and the Rb partial loss pattern were consistent with those of HPV‐associated ECAs. Six of 22 (27%) CLDN18‐positive GASs were also positive for p16, but their other features—such as CLDN18 expression and the Rb preserved pattern—were the same as in p16 negative GASs. Expression of CLDN18.2 mRNA but not CLDN18.1 mRNA was confirmed in both GASs and HPV‐associated ECAs. Conclusions: CLDN18 (43‐14A) emerged as a potential diagnostic and therapeutic marker for GAS. A minor subset of HPV‐associated ECAs also can be immunoreactive for CLDN18 and express CLDN18.2 mRNA, suggesting divergent gastric phenotypic differentiation. The caution is that GAS and HPV‐associated ECAs can share overlapping histological features and similar expression of CLDN18 and p16.


  • Obstetric Outcome After Trachelectomy for Cervical Cancer Without Uterine Artery Preservation

    by Atsuhiko Sakai, Hideaki Yahata, Takako Sugiura, Kazushige Nakahara, Ryo Kiyokoba, Nobutaka Hachisuga, Saki Kido, Ichiro Onoyama, Kazuo Asanoma, Kiyoko Kato

    Aim: A trachelectomy is a fertility‐preserving surgery that is performed for cervical cancer. Transecting the uterine arteries (UAs) during abdominal radical trachelectomy (ART) or abdominal modified radical trachelectomy (AmRT) has the advantage of simplifying other surgical procedures. However, the effect of UA transection on subsequent pregnancy outcome is unknown. The purpose of this study was to clarify the pregnancy outcomes in post‐RT pregnancies in which the UAs were not preserved. Methods: This was a retrospective cohort study of electronic case records involving pregnant women after ART and AmRT, which were managed at Kyushu University Hospital from January 2008 to July 2024. Results: Complications that often occur in pregnancies after ART and AmRT, such as antepartum bleeding, premature birth, and preterm premature rupture of membranes, were noted to the same degree after UA‐sparing ART. In contrast, abnormalities related to placental attachment, such as placenta previa and adherent placenta, occurred at a high rate after UA transection. Furthermore, compared to pregnancies with normal placentation, pregnancies with abnormal placentation had more blood loss during cesarean section (1150 g vs. 2289 g; p = 0.0004) and required blood transfusion more frequently (5.7% vs. 64.2%; p < 0.0001). Conclusions: Although ART and AmRT with UA transection may increase the risk of abnormal placentation and bleeding‐related complications during cesarean section, UA transection may not increase the risk of major obstetric complications after ART and AmRT. Therefore, UA transection should be considered during ART and AmRT due technical advantages.

  • Open Access

    The Short‐Term Impacts of Japan's 2024 Physician Working‐Hour Limits on Labor Conditions, Self‐Directed Professional Development, and Happiness Among Obstetrician‐Gynecologists

    by Yuto Maeda, Satoru Nakagawa, Kentaro Nakanishi, Eri Inoue, Daisuke Inoue, Saki Kido, Michiko Kido, Kaori Koga, Shunji Suzuki, Yukio Suzuki, et al.

    Objective: To examine the short‐term impacts of Japan's newly implemented physician working‐hour limits (April 2024) on working conditions, self‐directed professional development (SDPD), defined as activities undertaken outside working hours to enhance one's professional skills, and work‐related happiness among obstetrician‐gynecologists (OB‐GYNs). Methods: An online survey was conducted between July 8 and July 31, 2024, targeting 867 Japan Society of Obstetrics and Gynecology members. Five hundred and fourteen full‐time practitioners who had not changed workplaces around April 2024 and had no missing data were analyzed. Participants were stratified by regulation levels (A, B, C, discretionary labor system, those who don't know their own level), and their working hours, anticipated income, SDPD satisfaction, and happiness (0–10 scale) were assessed. We used multivariate linear regression to evaluate the influence of labor condition changes on happiness and explored interactions involving unpaid overtime, income changes, and SDPD satisfaction. Results: Compared with level A (up to 960 h of overtime per year), participants at levels B and C (up to 1860 h of overtime per year) reported significantly lower happiness ( p < 0.001). Most respondents observed no major shifts in working conditions since March 2024, yet about 40% did not record SDPD hours that meet the working hour requirement as official work time. Adjusted analyses revealed that decreased income and unsatisfactory SDPD significantly lowered happiness, whereas higher SDPD satisfaction increased it (β: −0.64 [−1.07, −0.21], −0.98 [−1.46, −0.50], and 0.90 [0.44, 1.35], respectively). Subgroup analysis indicated that rising unpaid overtime further reduced happiness among those dissatisfied with SDPD (−1.43 [−2.41, −0.45]). Conclusions: The new working‐hour limits had minimal impact on labor conditions in the short run. However, satisfaction with SDPD was positively associated with happiness, whereas anticipated decreases in income were correlated with lower happiness.

  • Open Access

    Olaparib maintenance therapy for recurrent adult granulosa cell tumors: A case report

    by Haruna Tsukahara, Ichiro Onoyama, Kazuhisa Hachisuga, Hiroshi Yagi, Hideaki Yahata, Kiyoko Kato

    Poly (ADP‐ribose) polymerase inhibitors (PARPi) are now available for advanced or recurrent epithelial ovarian cancer after platinum‐based chemotherapy; however, there is little known concerning the use of PARPi for adult granulosa cell tumors (AGCT). A 49‐year‐old woman, who previously had primary debulking surgery and a second surgery for a first intraperitoneal recurrence, received a surgery for a second intraperitoneal recurrence of AGCT. Although she received paclitaxel–carboplatin combination chemotherapy and a combination of bleomycin, etoposide, and cisplatin after the surgeries for the first and the second recurrences, respectively, the risk of a third recurrence was considered very high due to microscopic peritoneal dissemination. Olaparib administration was initiated based on a FANCA mutation, which results in homologous recombination deficiency. The patient has been recurrence‐free for over 4 years since the initiation of olaparib. This case highlights the possibility of using olaparib for AGCT with a homologous recombination gene mutation.

  • Open Access

    Retrospective analysis of treatment and prognosis for clear cell carcinoma of the uterine cervix: 15‐year experience at a single institution

    by Yusuke Inomata, Keisuke Kodama, Shoji Maenohara, Hiroshi Yagi, Masafumi Yasunaga, Ichiro Onoyama, Kazuo Asanoma, Hideaki Yahata, Yoshinao Oda, Kiyoko Kato

    Aim: Clear cell carcinoma of the uterine cervix (CCCUC) is a rare disease, accounting for 4% to 9% of cervical adenocarcinomas. Because it is so rare, its pathogenesis is largely unknown, and the standard treatment is unclear due to a lack of prospective studies. Our aim is to investigate the clinical features, treatment, and prognosis of CCCUC.Methods: We retrospectively evaluated the clinical characteristics, treatment choices, and outcomes of 12 patients with CCCUC treated at our institution between January 2009 and July 2024.Results: The median patient age was 62.5 years (range, 14–90 years). The most common stage was IB (IA, n = 3; IB, n = 4; IIB, n = 1; IIIC, n = 2; IVB, n = 2). Ten patients underwent surgery as initial treatment: 6 underwent radical hysterectomy plus pelvic lymphadenectomy (PLD) or sentinel lymph node biopsy (SLNB), with or without para‐aortic lymphadenectomy (PALD); 3 underwent modified radical hysterectomy plus PLD with or without PALD; and 1 underwent radical trachelectomy with SLNB as fertility‐preserving surgery. All patients underwent bilateral salpingo‐oophorectomy except for the patient who opted for radical trachelectomy. Five patients received adjuvant treatment: 3 received platinum‐based systemic chemotherapy (2 of whom had combination therapy with bevacizumab), and 2 received concurrent chemoradiotherapy. The median follow‐up was 43.5 months (range, 1–123 months). The 5‐year progression‐free survival rate was 64.5%.Conclusion: Systemic platinum‐based chemotherapy with bevacizumab may be more effective than concurrent chemoradiotherapy as adjuvant therapy for CCCUC.


  • Open Access

    Low-Grade Endometrial Cancer with Abnormal p53 Expression as a Separate Clinical Entity: Insights from RNA Sequencing and Immunohistochemistry

    by Kazuhisa Hachisuga, Minoru Kawakami, Hiroshi Tomonobe, Shoji Maenohara, Keisuke Kodama, Hiroshi Yagi, Masafumi Yasunaga, Ichiro Onoyama, Kazuo Asanoma, Hideaki Yahata, et al.

    Background: A molecular classification of endometrial cancer was developed based on an analysis of The Cancer Genome Atlas. In this classification, the group characterized by abnormal p53 immunohistochemical expression showed the poorest prognosis. However, there may be no need to apply a molecular classification in low-grade endometrial cancer. In this study, we investigated the clinical significance of abnormal p53 immunohistochemical expression in low-grade endometrial cancer. Methods: We obtained nine frozen samples of endometrial cancer [low-grade endometrial cancer with wild-type p53 expression (EClop53wt group): n = 3, low-grade endometrial cancer with abnormal p53 expression (EClop53ab group): n = 3, and high-grade endometrial cancer (EChi group): n = 3]. RNA sequencing was performed for each sample. All the samples passed RNA quality control. In addition, an immunohistochemical analysis was performed for 44 formalin-fixed paraffin-embedded samples. Results: Differentially expressed genes were identified in the RNA sequencing results (1811 genes between the EClop53ab group and the EChi group, and 1088 genes between the EClop53ab group and the EClop53wt group). In a principal component analysis, the EClop53ab group was more similar to the EClop53wt group than to the EChi group. In the immunohistochemical analysis, L1CAM expression was significantly less frequently observed in the EClop53ab group than in the EChi group. Moreover, p21 expression tended to be more frequently observed in the EClop53ab group than in the EChi group. Conclusions: In this study, the RNA sequencing and immunohistochemical results revealed that the EClop53ab group is a separate entity from the EChi group. While the abnormal p53 group is considered the most prognostically unfavorable in molecular classification, these findings suggest that routine molecular profiling is not necessary for patients with low-grade endometrial cancer. However, there is insufficient evidence to modify adjuvant treatment in low-grade endometrial cancer patients. Further investigation is needed on the clinical application of molecular classification to low-grade endometrial cancer.


  • Open Access

    Sentinel Lymph Node Detection Using SPECT and Gamma Probe in Low‐Risk Endometrial Cancer: Efficacy and Factors Associated With Detection Failure

    by Kazuo Asanoma, Hideaki Yahata, Keisuke Kodama, Kaoru Okugawa, Masafumi Yasunaga, Ichiro Onoyama, Hiroshi Yagi, Shoji Maenohara, Kazuhisa Hachisuga, Takuro Isoda, et al.

    Introduction: This study examined factors that affected sentinel lymph node (SLN) identification of patients with endometrial cancer having a preoperative estimation of low recurrent risk. Methods: This study included 97 patients with endometrial cancer who attempted to identify SLN using a uterine cervical injection of technetium‐99 m phytate under laparoscopic or robotic‐assisted surgery at our institute. A preoperative single photon emission computed tomography (SPECT) and intraoperative gamma probe were used to detect hot nodes. Multiple clinical factors, including age, body mass index (BMI), and so on, were investigated for their association with SLN mapping failure. Results: Among 97 cases, SPECT failed to detect SLN unilaterally in 38 cases (39%) and on both sides in 9 cases (9%). Meanwhile, the gamma probe failed to detect SLN unilaterally in 23 cases (24%) and on both sides in 3 cases (3%). While only age was significantly associated with SLN detection failure using the SPECT detection system, both age and BMI were significantly associated with SLN detection failure using the gamma probe detection system. When limiting to the preoperative SLN detection failure cohort of 47 cases, there was a strong association between intraoperative SLN detection failure and BMI, but not age. Conclusion: The SLN biopsy system was effectively applied to patients with endometrial cancer who underwent minimally invasive surgery (MIS). Attempts to improve SLN identification in older patients and those with obesity are warranted to obtain maximum benefits of MIS for low‐ or medium‐risk cases.